Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

The Role of Neoadjuvant Therapy in Pancreatic Cancer

February 20th 2019

Advances in Adjuvant Chemotherapy

February 20th 2019

The Search for Targetable Alterations in Pancreatic Cancer

February 20th 2019

The Changing Landscape of Pancreatic Cancer Treatment

February 20th 2019

Dr. Nelson on Novel Combination Therapies in Colorectal Cancer

February 19th 2019

Douglas A. Nelson, MD, Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses novel combination therapies in colorectal cancer (CRC).

Advanced HCC: What's Next?

February 18th 2019

Understanding How Best to Sequence in Advanced HCC

February 18th 2019

Durable Activity in Synergistic Combination for HCC

February 18th 2019

Anticipating Results of Checkpoint Inhibitors in HCC

February 18th 2019

Two Options for Checkpoint Inhibition in HCC

February 18th 2019

Comparative Data in Available TKIs for HCC

February 18th 2019

Optimizing Sequencing of Therapies in HCC

February 18th 2019

ASCO GI 2019 Update: REFLECT Study

February 18th 2019

Evolution of Systemic Therapy in HCC

February 18th 2019

Treatment Options for Locally Advanced HCC

February 18th 2019

Assessing Liver Function & Actionable Mutations in HCC

February 18th 2019

Genetic Profiling in HCC

February 18th 2019

Dr. Mizrahi on Bevacizumab as a Chemoprotectant in CRC

February 15th 2019

Jonathan Mizrahi, MD, hematology/oncology fellow, The University of Texas MD Anderson Cancer Center, discusses bevacizumab (Avastin) as a chemoprotectant in colorectal cancer (CRC).

Dr. Kasi on Role of Immunotherapy in mCRC

February 14th 2019

Pashtoon M. Kasi, MD, MBBS, MS, assistant professor of oncology and senior associate consultant in the Division of Hematology/Oncology at Mayo Clinic, discusses the role of immunotherapy in the treatment of patients with metastatic colorectal cancer.

Improving Care for Patients With Colon/Rectal Cancer

February 14th 2019